If You Invested in 20/20 Biolabs Inc (AIDX)

20/20 BioLabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for early detection and prevention of cancers and chronic diseases. The company trades on Nasdaq under the symbol AIDX and operates as a commercial-stage diagnostics company centered on the OneTest brand. Its model combines blood-based laboratory testing, machine-learning analytics, and software-enabled reporting to support disease-risk assessment and biomarker tracking.

The company's primary commercial product family is OneTest for Cancer, a multi-cancer early detection, or MCED, blood test. The test is based on a patented protein tumor marker methodology and machine-learning-derived analysis. 20/20 BioLabs positions this approach as distinct from MCED methods that rely solely on circulating tumor DNA, with company materials emphasizing protein biomarkers as a core element of its early-stage cancer screening methodology.

OneTest for Longevity is the company's chronic disease risk assessment and management product family. The test measures inflammatory biomarkers and uses AI-enabled analysis to calculate and display risk information for chronic diseases such as diabetes, dementia, and cardiovascular disease. The product also provides evidence-based dietary recommendations tied to biomarker levels and related disease-risk patterns. Company materials state that the Longevity solution uses IBM watsonx.ai as an AI application development environment, with IBM serving as an information technology provider rather than a medical provider.

20/20 BioLabs processes its tests in a College of American Pathologists accredited and Clinical Laboratory Improvement Amendments licensed laboratory in Gaithersburg, Maryland. The company's materials describe home-accessible sample collection using upper-arm capillary collection devices, as well as distribution through clinical and practitioner channels. Its commercial customer and end-market references include functional and integrative medicine practitioners, public-sector cancer screening programs, occupational health markets, firefighters, veterans, self-insured employers, and direct-to-consumer sales efforts.

The company also operates CLIAx, described as a shared CLIA laboratory model for overseas diagnostics start-ups seeking to launch novel laboratory tests in the United States without establishing their own independent laboratory. Its legacy business includes BioCheck, a field test kit used for screening suspicious powders for bioterror agents.

20/20 BioLabs is an emerging growth company and smaller reporting company in its SEC registration materials. Its public-company record includes registration statements, material-event reports, financial-results disclosures, and capital-structure filings associated with its Nasdaq listing and financing arrangements.